Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose Sugammadex after Neostigmine for Reversal of Neuromuscular Blockade
NCT05066035Phase 4Completed
- Sponsor
- Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi
- Start
- May 2013
- Primary completion
- Oct 2016
- Modality
- Biodegradable Polymers, Small Molecules
01
Overview
A Phase 4 trial of Sugammadex in Residual neuromuscular blockade (RNMB), sponsored by Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi. Started May 2013; status: completed.
02
Drugs
Sugammadex
03
Conditions
Residual neuromuscular blockade (RNMB)
Beyond the preview
Go deeper on NCT05066035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05066035.